Shares of Aditxt Inc. (ADTX) continue to slide in over-the-counter trading after the biotech company's third reverse stock split since November failed to prevent its removal from the Nasdaq exchange, raising existential questions about the firm's survival.
Three Splits, One Outcome: A Staircase to Delisting
This is Aditxt's third reverse share split in the past seven months and second such action this year.
The first, a staggering 1-for-113 split, took effect in November 2025.
A 1-for-8 split followed in March 2026,
and a 1-for-27 split came in May. Each was designed to artificially boost the share price above Nasdaq's $1.00 minimum. The company was denied the usual 180-day grace period because its cumulative reverse-split ratio over two years exceeded 250-to-1. The math is brutal: a shareholder who held 100 shares before November 2025 now owns a sliver of a single share.
Nasdaq Said No — And the Numbers Explain Why
On June 23, 2026, the Nasdaq Hearings Panel denied Aditxt's request to continue its listing, and trading was suspended on June 25.
The panel found that Aditxt reported stockholders' equity — essentially what's left after subtracting debts from assets — of negative $35.2 million, far below Nasdaq's $2.5 million minimum.
The panel also cited seven total reverse splits, continued losses of roughly $5 million per quarter, and skepticism about a proposed $150 million deal for its diagnostics subsidiary.
Almost Zero Revenue, Massive Losses
Over the trailing twelve months, Aditxt generated just $3,000 in revenue while posting an operating loss of $19.6 million.
Net losses totaled $43.1 million.
The company's market capitalization has shriveled to roughly $34,000 — less than many used cars.
A Last-Ditch Hail Mary
Aditxt is targeting a shareholder vote on July 23 for yet another reverse split and a September 14 vote on a deal it claims could deliver about $125 million in equity value through a merger of its Ignite Proteomics unit.
But Nasdaq's panel explicitly doubted the sustainability of that transaction, given continued losses, negative equity, and non-revenue subsidiaries.
Aditxt itself has warned that delisting raises "substantial doubt about its ability to continue as a going concern" and could force it to shut down, causing investors to lose everything.